Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy

Table 3 Univariate and multivariate analyses for DFS among patients with trastuzumab

Factor	Univariate	Multivariate		p-value
Factor	p-value	HR	95%CI	p-value
Age (≤40 vs. > 40)	< 0.001	3.907	1.551–9.840	0.004
T stage	0.417
(T2 vs. T1) (T3 vs. T1)
pN stage	< 0.001
(pN1 vs. pN0)		2.930	0.832–10.320	0.094
(pN2–3 vs. pN0)		9.478	3.026–29.681	< 0.001
Grade (3 vs. 1–2)	0.013			0.435
HR (negative vs. positive)	0.001	5.854	1.878–18.245	0.002
Ki67 (≥30% vs. < 30%)	0.574
pre-NLR (high vs. low)	0.003	2.917	1.055–8.062	0.039
NC (yes vs. no)	0.333

HR, hazard ratio; CI, confidence interval; NC, neoadjuvant chemotherapy; NLR, neutrophil/lymphocyte ratio; ALC, absolute lymphocyte count. Statistically significant factors are in bold font

ISSN: 1471-2407